1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,004 | 0,005 | 09:43 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.08. | Aptamer Group PLC - Appointment of Joint Corporate Broker | 1 | RNS | ||
| 14.08. | Aptamer Group PLC - Director Fee Shares and Grant of Options | - | RNS | ||
| 13.07. | Aptamer Group PLC - Trading Update | 1 | RNS | ||
| 09.07. | Aptamer Group moves into Ebola diagnostics | 1 | The Armchair Trader | ||
| 08.07. | Aptamer Group Begins Development of Rapid Test for Bundibugyo Ebola | 2 | Contract Pharma | ||
| APTAMER GROUP Aktie jetzt für 0€ handeln | |||||
| 08.07. | TRADING UPDATES: Brave Bison earnings jump; Aptamer begins Ebola work | 1 | Alliance News | ||
| 08.07. | Aptamer Group PLC - Aptamer initiates Ebola diagnostic test programme | 1 | RNS | ||
| 25.06. | Aptamer Group PLC - Programme and technical development update | 1 | RNS | ||
| 08.06. | Aptamer launches funded folic acid fortification testing programme | 4 | Sharecast | ||
| 08.06. | Aptamer Group PLC - Rapid testing programme for fortified foods | 1 | RNS | ||
| 13.04. | Aptamer Group PLC - Result of General Meeting | 1 | RNS | ||
| 31.03. | Aptamer Group PLC - Result of Retail Offer and Posting of Notice of GM | 1 | RNS | ||
| 26.03. | TRADING UPDATES: LPA to meet consensus; Aptamer raises GBP4.28 million | 3 | Alliance News | ||
| 26.03. | Aptamer Group PLC - Retail Offer to raise up to £0.5 million | 2 | RNS | ||
| 26.03. | Aptamer Group PLC - Results of Placing | - | RNS | ||
| 25.03. | Aptamer reports "meaningful" first-half progress alongside fundraise | 3 | Alliance News | ||
| 25.03. | Aptamer Group: Partnership cash helping to fund development | 1 | The Armchair Trader | ||
| 25.03. | Pharma-Verträge treiben Umsatz der Aptamer Group um 27 % | 1 | Investing.com Deutsch | ||
| 25.03. | Aptamer Group reports 27% revenue increase in first half | 2 | Investing.com | ||
| 25.03. | Aptamer Group PLC - Interim Results and Notice of Investor Webinar | 3 | RNS |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CG ONCOLOGY | 72,00 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| ERASCA | 16,040 | +0,06 % | FDA Fast Track Puts Erasca's (ERAS) Pancreatic Bet Center Stage | ||
| RELAY THERAPEUTICS | 18,890 | 0,00 % | Relay Therapeutics: Zovegalisib-Pipeline steht vor entscheidenden Meilensteinen | ||
| HARMONY BIOSCIENCES | 41,100 | 0,00 % | Harmony Biosciences stellt auf Cantor-Konferenz erweiterte Wachstumsstrategie vor | ||
| ADMA BIOLOGICS | 9,390 | 0,00 % | Kehoe Law Firm, P.C.: ADMA Biologics (ADMA) Shareholder Alert: Kehoe Law Firm Investigates Potential Fiduciary Duty Breaches | Philadelphia, Pennsylvania--(Newsfile Corp. - August 5, 2026) - Kehoe Law Firm, P.C. is investigating whether certain officers and directors of ADMA Biologics, Inc. ("ADMA," "ADMA Biologics," or... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 76,48 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen | |
| IMMUNOME | 24,970 | 0,00 % | Immunome: Varegacestat Cuts Progression Or Death Risk 84% As FDA Decision Targets April 2027 | ||
| TANGO THERAPEUTICS | 23,390 | +0,09 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 29,300 | 0,00 % | Mineralys auf Wells Fargo Konferenz: Markteinführung von Lorundrostat nimmt Gestalt an | ||
| DYNE THERAPEUTICS | 18,415 | -0,03 % | Aktien New York Ausblick: Dow schwächelt weiter - Nasdaq stabil erwartet | NEW YORK (dpa-AFX) - Die US-Börsen steuern nach dem verlängerten Wochenende am Dienstag auf eine durchwachsene Eröffnung zu. Auf die Stimmung drückten die weiter steigenden Ölpreise, die der Angst... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 10,580 | 0,00 % | Vir Biotechnology, Inc.: Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026 | - Oral presentation of complete Week 96 data from the Phase 2 SOLSTICE trial in chronic hepatitis delta selected for inclusion in "Best of EASL 2026" by EASL - Poster presentation of Week 48... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 111,42 | 0,00 % | Inhibrx Biosciences, Inc.: Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study | First OX40 agonist to demonstrate clinical benefit in a randomized study
INBRX-106 plus pembrolizumab delivers a 48.3% cORR and 72.4% of patients remain progression... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,020 | +0,12 % | Mercks 30-Milliarden-Dollar-Blockbuster bekommt neue Konkurrenz - warum Big Pharma schon die nächste Plattform sucht | ||
| VERA THERAPEUTICS | 33,560 | -0,12 % | Vera Therapeutics: Erfolgreicher Start für Nierenmedikament TRUTAKNA | ||
| KYMERA THERAPEUTICS | 117,00 | 0,00 % | Kymera Therapeutics auf Citigroup-Gipfel: Offensive bei oralen Immunologie-Medikamenten gewinnt an Fahrt |
APTAMER GROUP PLC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,002 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu APTAMER GROUP PLC finden Sie auf Wallstreet Online.